Brexit and Healthcare Industry – Implications for Pharma – Q2 2019

Pages: 50 Published: July 31, 2019 Report Code: GDHCHT028

It has been over three years since the UK voted to leave the EU. After the UK and the EU agreed to a second delay to Brexit, it is due to happen on 31 October, 2019 and negotiations are still ongoing to determine the UK’s relationship with the EU after Brexit.
This report provides an assessment of how the pharmaceutical industry expects Brexit to affect the healthcare sector, both within and outside of Britain. This study will be repeated in autumn this year, to gauge the changing sentiment towards Brexit from within the healthcare industry.

Scope

GlobalData’s Brexit and the Healthcare Industry – Implications for Pharma, Q2 2019 provides in-house analyst expertise on the results of a 10 minutes survey of 103 GlobalData Pharma clients and prospects which was fielded from July 2, 2019 to July 19, 2019. Participants answered questions about how they expected Brexit to affect the healthcare sector, both within and outside of the UK.

Components of the slide deck include:

• Outcomes of Brexit – Brexit outcome on October 31, best and most likely outcomes of Brexit providing respondent mix by geography

• Factors to Impact Healthcare—key factors to impact the post-Brexit UK healthcare industry providing respondent mix by region and seniority level as compared to previous survey waves in 2018 and 2019

• Impact on Research and Manufacturing — key factors to impact healthcare research and manufacturing in the UK post-Brexit providing respondent mix by region and seniority level as compared to previous survey waves in 2018 and 2019

• Impact on Corporate Strategy —level of impact of Brexit on corporate strategy providing respondent mix by region, seniority level, and headquarter location as compared to to previous survey waves in 2018 and 2019

• Impact on Relocation — impact of Brexit on staff and headquarter relocation as indicated by resondents whose headquarters is located in the UK as compared to to previous survey waves in 2018 and 2019

Reasons to Buy

Develop and design your corporate strategies post-Brexit through an in-house expert analysis of the key factors to impact the post-Brexit UK healthcare industry.

Develop business strategies by understanding the key factors to impact healthcare research and manufacturing in the UK post-Brexit.

Stay up to date on the industry’s changing sentiment towards Brexit from within the healthcare industry with quarterly surveys.

Identify emerging industry trends post-Brexit to gain a competitive advantage.

Table of Contents

1 Table of Contents (PowerPoint Deck)

1 Study Design

1.1 Abbreviations

1.2 Background, Objectives, and Design

1.3 Respondent Mix – Geography

1.4 Respondent Mix – Seniority Level

1.5 Respondent Mix – Headquarters Location

2 Executive Summary

2.1 Key Findings

2.2 Change in Brexit Sentiment Since Previous Wave (Q4 2018/Q1 2019)

3 Overview of UK Pharma Industry

3.1 The UK Pharma Industry – A Key Driver of the UK Economy

3.2 The UK as an Attractive Location for Clinical Trials

3.3 Brexit Timeline

4 Outcomes of Brexit

4.1 Brexit Outcome on October 31, 2019

4.2 Best and Most Likely Outcomes of Brexit – No Brexit Is the Best Outcome but Not the Most Likely

4.3 Best and Most Likely Outcomes of Brexit – A Closer Look at Geography

4.4 At Least Three Years Necessary to Stabilize the UK Healthcare Industry in a “No Deal” Brexit

4.5 Why Has Your Sentiment Changed Towards Brexit? – In Their Words

5 Factors to Impact Healthcare

5.1 Key Factors to Impact the UK Healthcare Industry After Brexit

5.2 Key Factors to Impact the UK Healthcare Industry After Brexit – A Closer Look at the Top Four Factors

6 Impact on Research and Manufacturing

6.1 Will Healthcare Research and Manufacturing Be Impacted Following Brexit? – Respondent Mix by Location

6.2 Will Healthcare Research and Manufacturing Be Impacted Following Brexit? – Respondent Mix by Seniority Level

6.3 Why the UK Will Be an Attractive Destination for Healthcare Companies

6.4 Why the UK Will Not Be an Attractive Destination for Healthcare Companies

7 Impact on Corporate Strategy

7.1 The Impact of Brexit on Corporate Strategy

7.2 The Impact of Brexit on Corporate Strategy, by Location – A Closer Look at the Numbers

7.3 The Impact of Brexit on Corporate Strategy, by Seniority Level

7.4 How Has Brexit Most Influenced Corporate Strategy? – Investing Resources into Managing the Potential Impact of Brexit Is a Major Concern

7.5 How Has Brexit Most Influenced Corporate Strategy? – In Their Words

8 Impact on Relocation

8.1 Potential of Relocation of Staff Due to Brexit – All Respondents

8.2 Potential of Relocation of Staff Due to Brexit – A Closer Look at Geography and Seniority Level

8.3 Relocation of Headquarters Unlikely After Brexit

9 Summary of Key Findings

10 Appendix

10.1 Related and Upcoming Reports

10.3 Sources

10.4 About the Authors

10.5 About Thematic Research

10.6 About Thematic Reports

10.7 About GlobalData

10.8 Contact Us

10.9 Disclaimer

$495

Can be used by individual purchaser only

$995

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods
Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.

Pharmaceuticals
New
Net Present Value Model: (borneol + edaravone)
$500 | November 2022
Pharmaceuticals
New
Net Present Value Model: (Aspirin + Dipyridamole) ER
$500 | November 2022